• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Health

More people are getting boosters than first doses of COVID vaccines right now

By
Marco Quiroz-Gutierrez
Marco Quiroz-Gutierrez
Down Arrow Button Icon
By
Marco Quiroz-Gutierrez
Marco Quiroz-Gutierrez
Down Arrow Button Icon
October 21, 2021, 2:58 PM ET

The Centers for Disease Control is meeting today to discuss which groups of people need booster shots of the Moderna and Johnson & Johnson vaccines, but the amount of people getting booster shots is already on the rise.

While the rate at which people getting a first dose of the COVID vaccine has slowed, the number of people receiving booster shots increased to 11.2 million, as of Thursday, from about 8.5 million last week.

That means 5.9% of all vaccinated people in the U.S. And 15.3% of vaccinated seniors have gotten a booster, so far, according to the most recent CDC data.

The Food and Drug Administration approved the Pfizer-BioNTech booster for certain populations in September, including those older than 65, adults with underlying medical conditions, and adults who work in high-risk settings.

On Wednesday, the FDA approved booster shots for the Moderna and Johnson & Johnson vaccines as well. The agency also declared that medical providers can now provide boosters of the three approved vaccines to anyone regardless of the brand of vaccine they received initially.

A CDC committee is meeting today to discuss its own recommendation for the Moderna and Johnson & Johnson boosters. Shots can typically begin to be administered after the CDC director signs off on the agency’s recommendation.

The mix-and-match authorization could reduce demand for a Johnson & Johnson booster because of the lower level of antibodies compared to those who received a Moderna or Pfizer booster.

According to a preprint paper released last week, all combinations of original vaccines with different brands of boosters were safe and all increased an individual’s antibody count after two weeks. The paper has not yet been peer-reviewed.

The FDA’s move will expand booster access to many more people, although some health experts have argued that younger people who have already received two shots don’t need a booster.

Yet, Pfizer Inc. And BioNTech SE reported Thursday that its booster was 95.6% effective against symptomatic COVID. The results are based on a study which followed 10,000 people aged 16 years and older, according to a statement the companies released Thursday.

Subscribe to Coins2Day Daily to get essential business stories straight to your inbox each morning.

About the Author
By Marco Quiroz-Gutierrez
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.